Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale” to Install Upright Proton Therapy System in Southern Italy

A significant expansion in radiotherapy capability is underway at Istituto Pascale as they are set to become the first proton therapy center in Southern Italy. 

NAPLES, ITALY – MAY 2026 – Istituto Nazionale Tumori di Napoli IRCCS “G. Pascale” has confirmed it will install a MEVION S250-FIT™ Proton Therapy System, representing a significant addition to the institute’s radiotherapy capabilities. 

The system is intended to support the development of a proton therapy program at the institute, that will allow access to advanced radiation therapy techniques for patients across Southern Italy for the first time. 

Proton therapy is a specialised form of radiation therapy that uses positively charged particles (protons) to deliver radiation to tumors. Unlike conventional X-ray (photon) radiotherapy, protons deposit most of their energy at a defined depth, which enables targeted dose delivery while reducing radiation exposure to surrounding tissues. 

The MEVION S250-FIT™ system incorporates an ultra-compact proton accelerator with upright positioning and imaging technologies, including integrated technology from Leo Cancer Care. Leo Cancer Care’s technology is designed to improve patient experience, support upright imaging and treatment within radiotherapy environments, and is incorporated as part of the overall system configuration. 

 “The selection of the MEVION S250-FIT reflects our commitment to bringing advanced, accessible cancer care to patients in Southern Italy,” said Dr. Paolo Muto, Ph.D., previous Director of Radiation Oncology at Istituto Nazionale Tumori IRCCS Fondazione G. Pascale. “Its ability to integrate into our existing clinical infrastructure while delivering state-of-the-art proton therapy was a decisive factor in our decision.” 

“Through our partnership with Mevion, our technology is being integrated into the S250-FIT™ system to support advanced radiotherapy environments and make this form of advanced radiotherapy more accessible,” said Stephen Towe, CEO of Leo Cancer Care. “We are pleased to contribute to this important installation at Istituto Pascale, advancing the availability of proton therapy to the people of Southern Italy.” 

When operational at a clinical level, the system is expected to support the treatment of a range of cancer types. This installation further strengthens Istituto Pascale’s role in oncology care and research and will make them the first proton therapy center in Southern Italy. 

*Please note that the MEVION S250-FIT™ system has received FDA 510(k) clearance and is CE-marked under Regulation (EU) 2017/745.